E. Avşar

发表

Ganciclovir-resistant cytomegalovirus encephalitis in a hematopoietic stem cell transplant recipient

B. Ferhanoğlu, A. Mert, R. Ozaras, 2010, Journal of NeuroVirology.

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

A. Varghese, D. Melisi, S. Estrem, 2021, Journal for ImmunoTherapy of Cancer.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

S. Jaeger, J. Schellens, H. Lenz, 2017, Cancer discovery.

The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth

Manway Liu, J. Dering, R. Finn, 2013, Molecular Cancer Therapeutics.

Chemical Therapeutics The HSP 90 Inhibitor NVP-AUY 922 Potently Inhibits Non – Small Cell Lung Cancer Growth

Manway Liu, J. Dering, R. Finn, 2013 .

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

W. Mason, D. Melisi, S. Estrem, 2021, Clinical Cancer Research.

Adenosine acting via A1 receptors, controls the transition to status epilepticus-like behaviour in an in vitro model of epilepsy

R. Empson, Emin Avşar, E. Avşar, 2004, Neuropharmacology.

PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

L. Sequist, E. Felip, E. Garon, 2012 .

Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).

J. Desai, J. Schellens, H. Lenz, 2016 .

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

S. Estrem, Jiangang Liu, L. Gandhi, 2023, BMC Cancer.

Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the {alpha}-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.

R. Bernards, J. Schellens, J. Tabernero, 2014 .

Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer

S. Jaeger, J. Schellens, H. Lenz, 2015 .

First-In-Human Phase I Study of a Next-Generation, Oral, TGF b Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

W. Mason, D. Melisi, S. Estrem, 2021 .